WELL, GOOD MORNING, EVERYONE.
WELCOME.
I'LL CALL THE OPEN SESSION OF
THE 116th MEETING OF NATIONAL
ARTHRITIS AND MUSCULOSKELETAL
SKIN DISEASES TO ORDER.
COUNCIL MEETINGS ARE OPEN TO THE
PUBLIC AS REQUIRED BY LAW EXCEPT
FOR THE REVIEW, DISCUSSION, AND
EVALUATION OF GRANT APPLICATIONS
AND RELATED INFORMATION WHICH WE
ADDRESSED THIS MORNING IN CLOSED
SESSION.
I ALSO WANT TO REMIND YOU THIS
MEETING IS BROADCAST BY NIH
VIDEOCAST AND IS ALSO BEING
RECORDED.
I'M GOING TO TURN THE MEETING
OVER TO DARREN TO GO OVER
LOGISTICS.
>> GOOD MORNING, WELCOME TO THE
SESSION OF COUNCIL.
IF ANY STAFF MEMBER WATCHING ON
VIDEOCAST HAS URGENT QUESTIONS,
E-MAIL SHALANDA WELLINGTON, MOST
OF YOU SHOULD HAVE HER E-MAIL
ADDRESS AND SHE CAN REFER
QUESTIONS TO ME.
WE ENCOURAGE VIEWERS TO SUBMIT
COMMENTS IN WRITING UP TO 15
DAYS FOLLOWING THE MEETING,
NIAMSCOUNCILMAIL@MAIL.NIH.GOV.
SO WE WILL CERTAINLY LOOK FOR
ANY COMMENTS THERE.
ANYONE ON TEAMS MAY SPEAK, BUT
MAKE SURE YOU MUTE YOUR LINE
WHEN NOT SPEAKING.
YOU MAY RAISE YOUR HAND, WE CAN
CALL ON YOU.
SHALANDA WILL HELP WITH MEETING
AND UNMUTING ESPECIALLY WHEN
TAKING VOTES.
AS MUCH AS POSSIBLE, KEEP YOUR
VIDEO ON.
IF YOU NEED COMPUTER SUPPORT OR
HELP WITH THE ELECTRONIC COUNCIL
BOOK CONTACT SHALANDA.
A NOTICE OF THE COUNCIL MEETING
WAS PUBLISHED IN THE FEDERAL
REGISTER, I'LL REMIND BUT
UPCOMING CONFLICT OF INTEREST
REPORTING DATES, UPDATES
REQUESTED IN FEBRUARY, JUNE, AND
OCTOBER.
WHEN YOU RECEIVE THE REQUEST,
PLEASE RESPOND WITHIN 30 DAYS IN
ORDER TO PARTS NATURE
COUNCIL-RELATED ACTIVITIES.
FURTHER INFORMATION REGARDING
CONFLICT OF INTEREST
SPECULATIONS ARE INCLUDED AGAIN
IN THE ELECTRONIC COUNCIL BOOKS.
MINUTES OF THE SEPTEMBER 17,
2024, COUNCIL MEETING ARE POSTED
IN THE ELECTRONIC COUNCIL BOOK.
THE REPORT OF THE BOARD WHICH
REVIEWS YOUR INTRAMURAL PROGRAM
IS ALSO PROVIDED THERE.
I WOULD FINALLY REMIND YOU OF
DATES OF FUTURE MEETINGS,
LOCATED IN THE ELECTRONIC
COUNCIL BOOK.
NEXT MEETING WILL BE JUNE 3,
2025.
WE'RE SETTING UP AS IN-PERSON OR
HYBRID MEETING.
GOING FORWARD HOPING TO PLAN
SPRING MEETINGS TO BE IN PERSON,
FALL MEETING HYBRID, WINTER
MEETING, JANUARY MEETING,
VIRTUAL.
WE VERY MUCH APPRECIATE YOUR
PARTICIPATION.
PLEASE MAKE SURE THESE DATES
THAT I'M GOING READ OFF ARE
AVAILABLE ON YOUR CALENDAR.
JUNE 3, THEN OCTOBER 14, 2025.
JANUARY 27, 2026, AND JUNE 2,
2026.
ALSO WE'LL BE HAVING -- WE'LL BE
PUTTING OUT A FEDERAL REGISTER
NOTICE RELATIVELY SOON, IN
AUGUST CLOSED SESSION ONLY
COUNCIL WE ARE STILL LOOKING FOR
A DATE FOR THAT, BUT ONCE WE
HAVE IT WE'LL BE INVITING YOU TO
THAT CLOSED SESSION OF COUNCIL.
IN GENERAL, I WAS GOING SAY WE
DID HAVE ORIGINALLY CONCEPT
CLEARANCE PRESENTATIONS TODAY.
WE'RE UNABLE TO PRESENT THOSE.
WE'LL DO THOSE AT THE JUNE
MEETING INSTEAD.
IF THERE ARE NO QUESTIONS ABOUT
THIS INFORMATION, I'M GOING TO
TURN BACK OVER TO DR. CRISWELL.
>> OKAY.
LET ME SHARE MY SCREEN HERE.
IT'S NOT SHARING.
>> IN YOUR DESKTOP.
>> THERE WE GO.
CAN YOU SEE THAT NOW?
>> YES, WE CAN SEE IT.
>> GREAT, OKAY.
AS I BEGIN, AS YOU HAVE READ IN
THE MEDIA WE HAVE A LOT GOING ON
THESE DAYS AT NIAMS AND NIH.
IN MARCH, THE U.S. DEPARTMENT OF
HEALTH AND HUMAN SERVICES
ANNOUNCED RESTRUCTURING EFFORT
WHICH WILL CENTRALIZE THE NIH'S
PROCUREMENTS, HUMAN RESOURCES,
AND COMMUNICATIONS ACROSS ITS 27
INSTITUTES AND CENTERS.
NIH GRANTS AND FUNDING POLICIES
ARE EVOLVING AS NIH ALIGNS WITH
NEW AGENCY PRIORITIES.
I ENCOURAGE YOU TO CHECK THE NIH
GRANTS AND FUNDING WEBSITE
REGULARLY FOR UPDATED
INFORMATION.
THIS IS A TIME OF TREMENDOUS
CHANGE AND WHILE I'M SURE THERE
ARE MANY QUESTIONS, THINGS ARE
EVOLVING.
I APPRECIATE YOUR PATIENCE AS WE
AT NIH IMPLEMENT CHANGES AS PART
OF A MAJOR HHS REORGANIZATION.
AND I LOOK FORWARD TO SHARING
UPDATES WITH YOU AS ADDITIONAL
INFORMATION BECOMES AVAILABLE.
BUT I WANT TO ASSURE YOU THAT
OUR COMMITMENT TO ADVANCING
RESEARCH THAT WILL IMPROVE THE
LIVES OF PEOPLE WITH AUTOIMMUNE,
BONE, JOINT, MUSCLE, RHEUMATIC
AND SKIN CONDITIONS REMAINS
STRONG.
WE LOOK FORWARD TO CONTINUING
OUR WORK WITH THE COUNCIL TO
IDENTIFY AND SUPPORT THE BEST
SCIENCE IN THESE AREAS AS
CONSISTENT WITH TH
ADMINISTRATION'S PRIORITIES.
I'M GOING TO START BY
INTRODUCING TWO COUNCIL MEMBERS
WHO WHILE AT OUR SEPTEMBER
MEETING WERE NOT FORMALLY
INTRODUCED AT THAT TIME.
MS. SHARON SMITH-TERRY, A
ORTHOPEDIC RESEARCH SOCIETY,
EXPERIENCE LEADING PROFESSIONAL
SOCIETIES WITH SERVICE TO THE
NEUROCRITICAL CARE SOCIETY AND
AMERICAN HOSPITAL ASSOCIATION,
BACKGROUND IN MARKETING,
COMMITMENT TO COMMUNITY THROUGH
NUMEROUS VOLUNTEER ACTIVITIES.
WE ALSO WELCOME DR. MELISSA
SPENCER, PROFESSOR OF NEUROLOGY
AT UCLA, SHE STUDIES MECHANISMS
UNDERLYING GENETICALLY INHERITED
NEUROMUSCULAR DISEASES SUCH AS
DUCHENNE MUSCULAR DYSTROPHY AND
LYNN GIRDLE MUSCULAR
DYSTROPHY
TO DEVELOP TREATMENTS FOR THESE
CONDITIONS.
WE'VE INVITED OUTSTANDING
INVESTIGATORS FROM THE NIAMS
POOL OF MENTORED K01, K08, K23
AWARD RECIPIENTS TO PARTICIPATE
IN THIS COUNCIL MEETING AS AD
HOC MEMBERS.
THE IDEA IS FAMILIARIZE THEM
WITH COUNCIL, ALLOW US TO ATTAIN
INPUT FROM SCIENTISTS AT AN
EARLIER CAREER STAGE THAN FULL
COUNCIL MEMBERS TYPICALLY ARE.
SO TODAY WE'RE JOINED BY DR.
SARAH GEBAUER AND KRISTIN
MORGAN.
DR. GEBAUER FROM ST. LOUIS
UNIVERSITY SCHOOL OF MEDICINE,
INTERESTS OF NEIGHBORHOOD AND
HEALTH, OSTEOARTHRITIS, USE OF
ADMINISTRATIVE DATA.
DR. MORGAN ASSOCIATE PROFESSOR
UNIVERSITY OF CONNECTICUT,
QUANTIFYING JOINT STABILITY,
HUMAN MOVEMENT, ASSESSING LOWER
EXTREMITY INJURY RISK.
I OFFER A WARM WELCOME TO YOU
BOTH.
I HOPE THAT YOU WILL PLEASE
PARTICIPATE IN DISCUSSIONS TODAY
AND PROVIDE YOUR VALUABLE
PERSPECTIVES ON ANY OR ALL
TOPICS WE COVER.
SO I NOW WANT TO CALL ON COUNCIL
MEMBERS AND KEY STAFF TO
INTRODUCE THEMSELVES.
THIS IS JUST FOR THE VIRTUAL
PARTICIPANTS.
AND I THANK YOU AND AM DELIGHTED
TO SEE ALL OF YOU.
I'LL STOP SHARING MY SCREEN SO
WE CAN DO THAT.
I ALSO WANT TO SAY I HOPE THAT
THIS BODY NOTICED WE'VE PROVIDED
COPIES OF THE BOARD OF
SCIENTIFIC COUNSELORS REPORT OF
OUR INTRAMURAL RESEARCH PROGRAM
AND TRIENNIAL REPORT FOR
CLINICAL TRIALS IN THE
ELECTRONIC COUNCIL BOOK.
WE APPRECIATE YOUR CAREFUL
REVIEW AND COMMENT ON THESE
IMPORTANT DOCUMENTS.
SO LET ME STOP SHARING SO WE CAN
DO SOME INTRODUCTIONS.
NOW, IT'S TRICKY HERE IN TEAMS
BECAUSE I'M NOT SEEING
EVERYBODY.
DARREN, ARE YOU IN A POSITION TO
CALL ON FOLKS ONE AT A TIME TO
INTRODUCE THEMSELVES?
YOU'RE MUTED.
>> YOU'RE STILL SHARING YOUR
DESKTOP, LINDSEY.
>> HOW ABOUT THIS.
IS THAT BETTER?
>> YES, THAT'S BETTER.
>> OKAY.
>> I'M GOING TO GO ACROSS AS I
SEE FOLKS IN THE VIDEO SO I HOPE
THE COUNSELORS HAVE THEIR VIDEO
ON.
LET ME TURN THAT OFF.
LET'S START WITH ED.
>> GOOD MORNING, ED BOATWAY,
GEORGIA TECH AND EMORY
UNIVERSITY, RESEARCH AREA IN
RESOLUTION PATHWAYS AND ROLE IN
WOUND HEALING AND
MUSCULOSKELETAL SYSTEM.
>> THANK YOU.
DR. MORGAN.
>> YES, DR. KRISTIN MORGAN,
FACULTY MEMBER AT THE UNIVERSITY
OF CONNECTICUT, BIOMARKER
ENGINEERING, HUMAN MOVEMENT
RESEARCH AND DEVELOPING NOVEL
REHABILITATION PROTOCOLS AND
OPTIMIZING MOVEMENT PATTERNS
THROUGH COMPUTATIONAL MODELING.
>> THANK YOU.
DOUG KIEL?
>> HI THERE.
I AM A PROFESSOR OF MEDICINE AT
HARVARD MEDICAL SCHOOL, SENIOR
SCIENTIST AT THE MARCUS
INSTITUTE FOR AGING INSTITUTE IN
BOSTON.
MY RESEARCH FOCUSES ON
MULTI-OMICS AND MUSCULOSKELETAL
DISEASE, CLINICAL TRIALS, AND
THE AGING OF THE MUSCULOSKELETAL
SYSTEM.
>> THANK YOU.
AND MY APOLOGIES FOR MOVING BACK
AND FORTH BETWEEN FIRST NAMES,
IT DEPENDS HOW LONG I'VE KNOWN
FOLKS.
STEPHEN, I THINK I'VE KNOWN YOU
LONG ENOUGH.
>> THANKS, DARREN.
STEPHEN TAYLOR, PRESIDENT AND
CEO ARTHRITIS FOUNDATION,
REPRESENTING 60 MILLION ADULTS,
HOUSE OF REPRESENTATIVES OF
THOUSANDS OF CHILDREN WITH
ARTHRITIS, VARIOUS FORMS,
HONORED TO BE HERE TODAY.
>> THANK YOU.
AND ANN ELDERKIN.
>> FORMER MANAGER, MANAGING
EDITOR OF SURGEON GENERAL'S
REPORT ON BONE HEALTH AND
OSTEOPOROSIS.
PLEASURE TO BE HERE.
>> THANK YOU.
MELISSA SPENCER.
>> SORRY.
DR. CRISWELL ALREADY DID GIVE
SOME BACKGROUND BUT I'M REALLY
HAPPY TO BE HERE, MELISSA
SPENCER, PROFESSOR OF NEUROLOGY,
I'M ALSO THE DIRECTOR OF THE
NEUROMUSCULAR PROGRAM IN
DEPARTMENT OF NEUROLOGY AT UCLA.
I'VE DONE BASIC SCIENCE IN
MUSCLE, MUSCLE BIOLOGY, AS WELL
AS TRANSLATIONAL RESEARCH AND
CLINICAL TRIALS IN UNDERSTANDING
PATHOGENESIS AND DEVELOPING
THERAPIES FOR THESE DISEASES.
>> THANK YOU.
DR. SMITH TERRY.
>> HELLO, SHARON SMITH TERRY,
CEO OF ORTHOPEDIC RESEARCH
SOCIETY, WE'RE THE LEADING
RESEARCH SOCIETY GLOBALLY THAT
DOES RESEARCH IN
MULTI-DISCIPLINARY AREAS OF MSK,
SO HAPPY TO BE HERE.
>> THANK YOU.
DR. GEBAUER.
>> HI, SARAH GEBAUER, FAMILY
SUGGESTION, TRANSLATIONAL
EPIDEMIOLOGIST ST. LOUIS
UNIVERSITY SCHOOL OF MEDICINE,
ST. LOUIS, MISSOURI.
RESEARCH IS FOCUSED ON THE
INTERSECTION OF ADMINISTRATIVE
HEALTH DATA LIKE ELECTRONIC
HEALTH RECORD DATA AND
GEOSPATIAL INFORMATION SCIENCE
SO WE CAN BETTER UNDERSTAND HOW
THE MILIEU THAT SOMEONE LIVES
IN, WORKS, IN GROWS UP IN, MAY
IMPACT SOMEONE'S IN THIS CASE
PREVALENCE OF OSTEOARTHRITIS OR
TRAJECTORY IN TERMS OF TREATMENT
AND THERAPIES.
>> THANK YOU.
CARL?
>> GOOD MORNING, EVERYONE.
CARL JUSTIN, ASSOCIATE DEAN FOR
RESEARCH, U OF M SCHOOL OF
MEDICINE, AREA OF RESEARCH IS IN
COMPLEX ADAPTIVE SYSTEMS, I
STUDY BONE PRIMARILY TO IDENTIFY
EARLY INDICATORS OF FRAGILITY.
THANK YOU.
>> THANK YOU.
>> BECKY MINNILLO.
>> CONDUCTING SKIN RESEARCH,
GLAD TO BE HERE.
>> BETH McNALLY.
>> BETH McNALLY, NORTHWESTERN
UNIVERSITY STEINBERG SCHOOL OF
MEDICINE, PHYSICIAN AND
SCIENTIST, LEAD OUR CENTER FOR
GENETIC MEDICINE, AS LONG AS --
LONG STAND HAVING IN MUSCULAR
DYSTROPHIES, INTERESTED IN
MODIFIERS AND THERAPIES.
>> THANK YOU.
AIMEE PAYNE
>> AIMEE PAYNE, PROFESSOR AND
CHAIR OF DERMATOLOGY, COLUMBIA
UNIVERSITY, PRESIDENT OF SOCIETY
FOR INVESTIGATIVE DERMATOLOGY,
MECHANISMS AND TREATMENT OF
AUTOIMMUNITY, PARTICULARLY
CELLULAR THERAPIES.
>> CHIEF OF DIVISION OF
RHEUMATOLOGY, SAN FRANCISCO
GENERAL, PROFESSOR OF MEDICINE
AT UCSF, I STUDY EPIDEMIOLOGY
AND OUTCOMES OF RUMOR MATTIC
DISEASES.
>> THANK YOU.
AND DR. LEE.
>> HI, I'M A STAFF PROFESSOR
FROM DEPARTMENT OF BIOMARKER
ENGINEERING, DIRECTOR OF THE
PROGRAM OF ADVANCED
MUSCULOSKELETAL IMAGING
CLEVELAND LYNNIC, RESEARCH ON
BIOTECHNICAL DEVELOPMENTS AND
CLINICAL TRANSLATION OF IMAGING
FOR DISORDERS TO IMPROVE EARLY
DIAGNOSIS AND PROGNOSIS.
A PLEASURE AND HONOR TO BE HERE.
THANK YOU.
>> THANK YOU.
I THINK WE GOT ALL OF OUR
COUNSELORS.
LET ME HAVE SOME OF THE STAFF
WHO ARE NOT IN THE ROOM WITH ME
INTRODUCE THEMSELVES.
I'LL START WITH ANNA.
>> ANNA MIZUKO, DEPUTY DIRECTOR,
LINDSEY WILL INTRODUCE THAT IN A
LITTLE BIT BUT IT'S REALLY GREAT
TO MEET YOU ALL TODAY.
THANKS SO MUCH.
>> AND TAMARA.
>> TAMARA ELLISON, NEW
SCIENTIFIC DIRECTOR, I'LL SHARE
MORE LATER.
GREAT TO BE WITH YOU TODAY.
>> AND WE HAVE A LOT OF PEOPLE
IN THE ROOM.
I'LL CALL ON A COUPLE TO
INTRODUCE THEMSELVES.
TO MY RIGHT GAIL.
>> GAYLE LESTER, DIRECTOR OF
EXTRAMURAL RESEARCH.
>> AND MARY?
>> HELLO, GOOD MORNING.
YES, GOOD MORNING STILL.
>> BOB CARTER IS ON.
WOULD LOVE TO --
>> GOOD MORNING, BOB CARTER,
EX-DEPUTY DIRECTOR, AND NOW
ADVISING LINDSEY ON THE VARIOUS
PROJECTS GOING ON AND TRYING TO
FIGURE OUT HOW TO NAVIGATE IN
THE CURRENT CONTEXT.
THANKS.
>> I THINK WE'RE OKAY.
>> LET ME -- IF THERE ARE OTHERS
WHO WOULD LIKE TO INTRODUCE
THEMSELVES OR IF QUESTIONS COME
UP AND PROGRAM OFFICERS SPEAK UP
PLEASE INTRODUCE YOURSELF IF WE
HAVEN'T DONE SO.
IF ANYBODY ELSE WOULD LIKE TO
SAY HELLO PLEASE FEEL FREE.
AND IF NOT, I THINK I'LL GO BACK
TO MY SLIDES.
FORGIVE ME FOR A MINUTE.
JUST LET ME GET THIS BACK UP
AGAIN.
OKAY, CAN YOU SEE IT AGAIN?
>> YES.
>> OKAY, GREAT.
SO, MY REPORT TODAY IS GOING TO
FOCUS ON THREE TOPICS.
FIRST I'LL COVER SOME PERSONNEL
CHANGES AT THE DEPARTMENT OF
HEALTH AND HUMAN SERVICES, NIH
AND NIAMS.
THEN I'LL TOUCH UPON NIH AND
NIAMS BUDGET AND SHARE NIH AND
NIAMS ACTIVITIES THAT MAY BE OF
GENERAL INTEREST.
SO, I'LL START BY ANNOUNCING
LEADERSHIP UPDATES I'M SURE YOU
ARE AWARE OF FROM THE NEWS.
BUT ON FEBRUARY 13, MR. ROBERT
F. KENNEDY JR. WAS SWORN IN AS
26th SECRETARY, FOLLOWING
NOMINATION BY PRESIDENT TRUMP
AND CONFIRMATION BY U.S. SENATE.
SECRETARY MR. KENNEDY WILL
OVERSEE ALL HHS PROGRAMS
OPERATING DIVISIONS AND
ACTIVITIES INCLUDING NIH.
AFTER GRADUATING FROM HARVARD
STUDIED AT LONDON SCHOOL OF
ECONOMICS, LAW DEGREE FROM
UNIVERSITY OF VIRGINIA LAW
SCHOOL, ALSO HOLDS MASTER DEGREE
IN ENVIRONMENTAL LAW FROM PACE
UNIVERSITY SCHOOL OF LAW.
SHIFTING NOW TO NIH, JAY
BHATTACHARYA STARTED ON APRIL 1
OF THIS YEAR, PRESIDENT TRUMP
NOMINATED HIM FOR THE POSITION
ON NOVEMBER 26 OF 2024, AND U.S.
SENATE CONFIRMED HIM ON MARCH
25, 2025.
HE PREVIOUSLY HELD A TENURED
PROFESSORSHIP IN MEDICAL SCHOOL
AT STANFORD UNIVERSITY IN
CALIFORNIA.
AND HIS RESEARCH FOCUSED ON
POPULATION AGING, AND CHRONIC
DISEASE, PARTICULARLY HEALTH AND
WELL-BEING OF VULNERABLE
POPULATIONS.
BEFORE JOINING STANFORD, HE
CONDUCTED RESEARCH AT THE
NATIONAL BUREAU OF ECONOMIC
RESEARCH AND SPHERE INSTITUTE, A
POLICY RESEARCH FIRM.
HE WAS ALSO AN ECONOMIST AT RAND
CORPORATION, VISITING ECONOMICS
PROFESSOR AT UCLA IN LOS
ANGELES.
HE EARNED A BACHELOR'S AND
MASTER'S DEGREES IN ECONOMICS
FROM STANFORD, COMPLETED MEDICAL
SCHOOL AND EARNED A Ph.D. IN
ECONOMICS ALSO FROM STANFORD
UNIVERSITY.
AND MOVING CLOSER TO HOME I'M
PLEASED TO ANNOUNCE NIAMS HAS A
NEW DEPUTY DIRECTOR, WHO YOU
JUST MET, DR. ANNA MAZZUCCO,
JOINED FROM THE NIH DIVISION OF
PROGRAM COORDINATION PLANNING
AND STRATEGIC INITIATIVES, ALSO
KNOWN AS DPCPSI, AS A SENIOR
ADVISER TO THE DPCPSI DIRECTOR,
AFTER PREVIOUSLY SERVING AS
NIH'S ACTING ASSOCIATE DEPUTY
DIRECTOR IN THE IMMEDIATE OFFICE
OF THE DIRECTOR.
SHE EARNED A Ph.D. FROM
HARVARD MEDICAL SCHOOL, APPLIED
SYSTEMS BIOLOGY APPROACHES TO
UNDERSTANDING MOLECULAR
INTERPLAY BETWEEN CELLULAR AGING
AND GROWTH CONTROL, WORKED AT
NON-PROFIT ORGANIZATION IN
WASHINGTON, D.C. ADDRESSING
WOMEN'S HEALTH AND CLINICAL
TRIALS.
WE'RE DELIGHTED THAT SHE HAS
DECIDED TO MAKE NIAMS HER HOME
FOR THE NEXT PHASE OF HER
CAREER.
AND LET ME STOP SHARING A MOMENT
SO DR. MAZZUCCO CAN OFFER A
COUPLE COMMENTS.
>> THANK YOU.
IT'S REALLY A PLEASURE TO MEET
YOU ALL AND I LOOK FORWARD TO
BEING ABLE TO MEET IN PERSON
WHEN WE'RE ABLE TO DO THAT AND
AS DR. CRISWELL SAID I CAME ON
DETAIL LAST YEAR, AND IT'S JUST
BEEN WITH WONDERFUL TIME GETTING
TO KNOW NIAMS.
I WAS DELIGHTED TO BE ABLE TO
MAKE THIS MY HOME AND I'VE
ENJOYED WORKING WITH LINDSEY AND
BOB AND ALL THE REST OF THE
NIAMS TEAM AND GETTING TO BETTER
KNOW OUR RESEARCH AREAS AND I
JUST REALLY LOOK FORWARD TO
WORKING WITH ALL OF YOU.
SO THANK YOU SO MUCH.
>> AND ANNA'S DEEP KNOWLEDGE OF
NIH INCLUDING OFFICE OF DIRECTOR
HAS BEEN EXTREMELY VALUABLE
DURING THIS TIME.
THANK YOU.
I'LL GET GOOD AT SHARING AND
UNSHARING IN TEAMS, I CAN SEE.
LET ME GO BACK AND SHARE AGAIN.
HOPEFULLY THAT'S BACK ON.
>> YES.
>> I'M ALSO PLEASED TO ANNOUNCE
AFTER A HIGHLY COMPETITIVE AND
OPEN SEARCH WE'VE APPOINTED DR.
TAMARA ALLISON AS SCIENTIFIC
DIRECTOR OF NIAMS INTRAMURAL
RESEARCH PROGRAM.
SHE WAS CHOSEN FOR THIS
IMPORTANT ROLE DUE TO
DEMONSTRATED SUCCESS IN
SCIENTIFIC RESEARCH, EXECUTIVE
EXPERIENCE, AND PROGRAMMATIC
LEADERSHIP.
BEFORE JOINING NIAMS, DR.
ALLISTON PROGRESSED AT THE
UNIVERSITY OF CALIFORNIA, SAN
FRANCISCO, MOST RECENTLY AT
PROFESSOR IN DEPARTMENT OF
ORTHOPEDIC SURGERY AT UCSF,
UNDERGRADUATE DEGREE IN BIOLOGY
FROM TRINITY UNIVERSITY IN SAN
ANTONIO, TEXAS, DOCTORAL DEGREE
IN CELL BIOLOGY FROM BAYLOR
COLLEGE OF MEDICINE.
DR. ALLISTON IN INTERESTED IN
DEVELOPING THE NEXT GENERATION
OF SCIENTISTS AND LEADERS, TO
IDENTIFY MULTI-SCALE MECHANISMS
OF SKELETAL DISEASE TO ADVANCE
DEVELOPMENT OF THERAPEUTIC
STRATEGIES.
THIS WORK WILL BUILD ON THE
ACCOMPLISHMENTS OF HER
LABORATORY OVER THE PAST 20
YEARS INVESTIGATING CROSS-TALK
OF BIOCHEMICAL AND PHYSICAL CUES
IN THE SKELETON, DR. ALLISTON
ASSUMES THE ROLE VACATED BY DR.
JOHN O'SHEA, WHO HAS ADDRESSED
THIS COUNCIL BEFORE AND WILL
MAKE IMPORTANT CONTRIBUTIONS TO
NIH THROUGH THE GROUNDBREAKING
WORK OF THE LABORATORY, I THANK
HIM FOR LEADERSHIP AND
SCIENTIFIC ADVANCES BUT NOW
WOULD LIKE TO GIVE DR. ALLISTON
A FEW MOMENTS TO SPEAK WITH YOU.
LET ME STOP SHARING AGAIN.
>> IT'S GREAT TO BE HERE WITH
YOU.
I AM SO PROUD TO BE A PART OF
THIS NIAMS LEADERSHIP TEAM.
IT'S BEEN WONDERFUL TO WORK WITH
EVERYONE HERE UNDER DR.
CRISWELL'S EXEMPLARY LEADERSHIP,
ESPECIALLY IN THIS TIME OF
TRANSITION.
I'M ALSO PROUD TO FOLLOW ON THE
GREAT WORK DR. O'SHEA HAS
ACCOMPLISHED FOR SO MANY YEARS
LEADING THE INTRAMURAL RESEARCH
PROGRAM AND ITS OUTSTANDING
CADRE OF INVESTIGATORS PUSHING
THE FIELD FORWARD IN
RHEUMATOLOGY, MUSCLE, SKIN, AND
SKELETAL DISEASE, AND I THINK
THAT THE RESEARCH THAT MY TEAM
BRINGS TO THE TABLE WILL
COMPLEMENT THAT AND HELP US TO
BUILD A STRONGER CROSS-NIH
COMMUNITY OF INVESTIGATORS,
ESPECIALLY THINKING, FOLLOWING
WHAT'S HAPPENED IN RHEUMATOLOGY
AND INFLAMMATORY DISEASE,
LOOKING FORWARD TO PARTNERSHIPS
BETWEEN INTRAMURAL AND
EXTRAMURAL RESEARCH AND LOOK
FORWARD TO INTERACTING WITH YOU
IN THIS EXCITING ROLE.
THANK YOU.
>> THANK YOU.
SHE'S BEEN DOING A FABULOUS JOB
DURING VERY UNUSUAL TIMES.
SO THANK YOU SO MUCH.
OKAY.
>> WE MUST CELEBRATE DR. GALE
LESTER'S PLAN TO RETIRE AT THE
END OF THE MENTHOL CIGARETTES,
THE -- THE MONTH.
SHE WAS PROGRAM DIRECTOR, SERVED
AS PROJECT OFFICER FOR
OSTEOARTHRITIS INITIATIVE, THE
FIRST NIH PUBLIC/PRIVATE
PARTNERSHIP THROUGH THE
FOUNDATION FOR NIH, SERVES AS
PROJECT DIRECTOR FOR A ANOTHER
FMIH PROJECT, STUDY TO ADVANCE
BMD AS REGULATORY ENDPOINT.
WE'LL MISS HER LEADERSHIP AND
COMMITMENT TO EXCELLENCE.
WHILE WE SEARCH FOR A
REPLACEMENT DR. MARY GARCIA WILL
SERVE AS INTERIM DIRECTOR OF THE
DIVISION.
SEVERAL OF YOU KNOW MARY BECAUSE
SHE'S BEEN WITH NIAMS AS GAYLE'S
DEPUTY SINCE SPRING OF 2023.
SHE WAS AT THE OFFICE OF DISEASE
PREVENTION BEFORE THAT,
SCIENTIFIC ADVISORY TO TOBACCO
REGULATORY PROGRAM SINCE 2014.
THANKS VERY MUCH TO MARY FOR
STEPPING UP AND THANK YOU,
GAYLE, FOR YOUR LEADERSHIP AND
SERVICE.
WE ALSO WELCOME TWO NEW PROGRAM
DIRECTORS WHO JOINED THE
INSTITUTE SINCE OUR LAST
MEETING.
DR. MELISSA PARKER JOINS FROM
OFFICE OF DISEASE PREVENTION,
WHERE SHE SERVED AS SCIENTIFIC
ADVISORY TO OFFICE'S FLAGSHIP
P2P PROGRAM, SHE HAS HELD
SEVERAL POSITIONS AT THE NIH,
INCLUDING A Ph.D. IN
BIOCHEMISTRY AND MOLECULAR
BIOLOGY, FROM INDIANA UNIVERSITY
SCHOOL OF MEDICINE, POSTDOCTORAL
TRAINING AT KANSAS STATE
UNIVERSITY, RESEARCH ASSOCIATE
AT MOREHOUSE SCHOOL OF MEDICINE.
DR. ANITA UNDALE, COMES FROM THE
NATIONAL CANCER INSTITUTE, LIKE
DR. PARKER SHE HAS EXPERIENCE IN
SEVERAL CAPACITIES AT THE NIH,
INCLUDING NIAMS INTRAMURAL
RESEARCH PROGRAM WHERE SHE
WORKED WITH OUR CLINICAL
DIRECTOR DR. BOB COLBERT.
DR. UNDALE OBTAINED M.D. IN
INTERNAL MEDICINE, FELLOWSHIP IN
PATHOLOGY, UNIVERSITY OF MUMBAI
IN INDIA, Ph.D. IN IMMUNOLOGY
FROM MAYO GRADUATE SCHOOL IN
MINNESOTA.
WELCOME TO YOU BOTH.
NIH IS CURRENTLY OPERATING UNDER
THE FULL YEAR CONTINUING
APPROPRIATIONS AND EXTENSIONS
ACT OF 2025.
REFERRED TO AS HR 1968.
WHICH PRESIDENT SIGNED ON MARCH
15, 2025.
THIS MEANS OUR ENACTED BUDGET
EQUALS COMPARABLE BUDGET ENOUGH
FROM 2024 FISCAL YEAR.
CONSISTENT WITH OUR PREVIOUS
PRACTICE IN RECENT YEARS WE'VE
DECIDED AT THE BEGINNING OF THE
FISCAL YEAR TO SET OUR PAYLINE
AT THE 8th PERCENTILE TO ALLOW
THE INSTITUTE MORE FLEXIBILITY
TO LOOK CRITICALLY AT GRANTS IT
FUNDS.
OUR PROGRAM DIRECTORS WILL
CONTINUE TO SCRUTINIZE THE
MERITORIOUS APPLICATIONS IN
PORTFOLIOS THAT SCORE BEYOND THE
PAYLINE TO IDENTIFY HIGH PRIVATE
PROJECTS FOR THE INSTITUTE TO
FUND.
I'LL START THIS SECTION OF MY
REPORT ABOUT NIH AND NIAMS
ACTIVITIES BY ANNOUNCING FISCAL
YEARS 2025 TO 2029 NIAMS
STRATEGIC PLAN ALONG WITH FACT
SHEET SUMMARY HAS BEEN
PUBLISHED.
AS YOU KNOW THIS PLAN WAS
DRAFTED WITH EXTENSIVE INPUT
FROM YOU AS COUNCIL MEMBERS,
EXTRAMURAL AND INTRAMURAL
RESEARCHERS, HEALTH CARE
ADVOCATES AND PROFESSIONAL
ORGANIZATIONS.
I EXPRESS APPRECIATION FOR THE
HARD WORK THAT WENT INTO
DEVELOPING A STRATEGIC PLAN.
ORGANIZED AROUND FOUR GOALS AND
TEN PRIORITIES REFLECTING THE
DREGS --
DIRECTION OF THE MISSION.
MANY PRIORITIES ARE ALREADY
BEING PURSUED BY EXTRAMURAL AND
INTRAMURAL RESEARCHERS.
FOR EXAMPLE, I WANT TO
ACKNOWLEDGE AND CONGRATULATE
THREE RESEARCHERS WHO
SUCCESSFULLY COMPETED FOR THE
NIH OFFICE OF AUTOIMMUNE DISEASE
RESEARCH AWARD FOR WORK UNDER
OUR PLAN PRIORITY NUMBER 1,
WHICH STUDY MOLECULAR AND
CELLULAR MECHANISMS OF HEALTH
AND DISEASE IN HUMANS, AND
UNDERSTANDING RESULTING
PHENOTYPES AND ENDOTYPES, USING
AN ESTABLISHES INCLUSIVE AND
WELL PHENOTYPED DATABASE AND
BIOREPOSITORY TO IDENTIFY CD8
POSITIVE T CELLS WHOSE CLONAL
EXPANSION IMPLICATES A
PATHOGENIC CONTRIBUTION TO AXIAL
SPONDYLOARTHRITIS PROGRESSION TO
DEVELOP TESTING TO ENABLE
EARLIER DIAGNOSIS, TOOLS TO
EXPLORE PATHOGENESIS OF DISEASE,
AND IN THE LONGER TERM TO
DEVELOP NOVEL THERAPEUTICS.
DR. NAGAO WILL DISCUSS
INTERACTION OF HUMAN HERPES
VIRUS WITH IMMUNE CELLS IN
CONTEXT OF DRUG INDUCED
HYPERSENSITIVITY SYNDROME.
HIS GOAL TO UNDERSTAND HOW THIS
VIRUS WHEN REACTIVATED IN
CONTEXT OF THE SYNDROME MIGHT
CONTRIBUTE TO BREAKDOWN OF
IMMUNOLOGIC TOLERANCE WHICH
RESULTS IN THE DEVELOPMENT OF
AUTOIMMUNE DISEASE.
OTHER EXCITING NEWS FROM THE NIH
OFFICE OF RESEARCH ON WOMEN'S
HEALTH OF WHICH THE OFFICE OF
AUTOIMMUNE DISEASE RESEARCH IS A
PART INCLUDES AN AWARD CO-FUNDED
BY NIAMS TO COLUMBIA UNIVERSITY
TO OVERSEE THE NEW NEXUS OR
NETWORK FOR EXPOSOMICS IN THE
U.S. COORDINATING CENTER FOR
RESEARCH ON THE HUMAN
EX-EXPOSOME AND EFFECTS ON
HEALTH REPRESENTING CUMULATIVE
MEASURE OF ENVIRONMENTAL
EXPOSURES AND CORRESPONDING
BIOLOGICAL RESPONSES.
IN ADDITION TO SUPPORTING THE
USE OF EXPOSOMICS ANON NIH
CENTERS NEXUS WILL ENGAGE WITH
ACADEMIC, COMMUNITY AND INDUSTRY
PARTNERS IN THE U.S. AND AROUND
THE WORLD.
IT WILL SUPPORT SCIENTIFIC BOOT
CAMPS, CONFERENCES, OTHER
LEARNING OPPORTUNITIES TO GROW
EXPOSOMICS AS A FIELD WITH
EMPHASIS ON OVERCOMING
SOCIOECONOMIC INEQUITIES.
BEFORE I OPEN THE FLOOR FOR
DISCUSSION, I WANT TO MAKE SURE
YOU'RE AWARE OF TWO NIH-WIDE
POLICY CHANGES.
STARTING THIS PAST JANUARY, MOST
RESEARCH PROJECT GRANT
APPLICATIONS SUBMITTED TO NIH
WILL BE ASSESSED USING
SIMPLIFIED REVIEW CRITERIA THAT
NIH ESTABLISHED TO ADDRESS
COMPLEXITY OF THE PEER REVIEW
PROCESS AND POTENTIAL FOR
REPUTATIONAL BIAS TO AFFECT PEER
REVIEW OUTCOMES.
THESE CHANGES HAVE BEEN IN THE
WORKS FOR SOME TIME, AS THE
CENTER FOR SCIENTIFIC REVIEW
DIRECTOR DR. NONI BYRNES SHARED
AT OUR JUNE 2023 COUNCIL
MEETING.
THE SIMPLIFIED FRAMEWORK FOR NIH
PEER REVIEW CRITERIA RETAINS
FIVE REGULATORY CRITERIA,
SIGNIFICANCE, INVESTIGATORS,
INNOVATION, APPROACH, AND
ENVIRONMENT, BUT REORGANIZES
THEM INTO THREE FACTORS.
TWO WILL RECEIVE NUMERICAL
CRITERION SCORES, ONE OF THE
FACTORS WILL BE EVALUATED SIMPLY
FOR SUFFICIENCY.
ALL THREE FACTORS WILL BE
CONSIDERED.
REFRAMING OF CRITERIA SERVES TO
FOCUS ON THREE CENTRAL QUESTIONS
REVIEWERS SHOULD BE EVALUATING.
HOW IMPORTANT IS THE PROPOSED
RESEARCH?
HOW RIGOROUS AND FEASIBLE ARE
THE METHODS?
AND WHETHER THE INVESTIGATORS
AND INSTITUTIONS HAVE THE
EXPERTISE AND RESOURCES
NECESSARY TO CARRY OUT THE
PROJECT.
OF PARTICULAR NOTE THESE CHANGES
IMPACT HOW AN APPLICATION IS
REVIEWED, THEY DO NOT CHANGE HOW
THE APPLICATION IS DEVELOPED.
REVIEWERS WILL BE PROVIDED
TRAINING AND GUIDANCE MATERIALS
IN THE SPRING OF 2025, IN TIMES
OF FIRST REVIEW MEETINGS THAT
INCLUDE SIMPLIFIED PEER REVIEW
FRAMEWORK IN SUMMER 2025.
YOU LIKELY HEARD ON MARCH 6 NIH
ANNOUNCED PLANS TO CENTRALIZE
PEER REVIEW OF APPLICATIONS
WITHIN THE NIH CENTER FOR
SCIENTIFIC REVIEWERS, CSR.
WE'RE NIAMS APPLICANTS TO OUR
CLINICAL TRIALS NOTICES OF
FUNDING OPPORTUNITIES, CENTER
PROGRAMS, OR A FEW OTHER FUNDING
OPPORTUNITIES, THIS MEANS THAT
THE NIH WILL DISCONTINUE OUR AMS
AND AMAC STUDY COMING TO THE
JUNE COUNCIL.
WE'LL PROVIDE UPDATES ON
CENTRALIZATION EFFORTS AT JUNE
MEETING.
NOW, TO FURTHER NIH'S COMMITMENT
TO PRINCIPLES OF TRANSPARENCY
AND ACCESSIBILITY IN NIH-FUNDED
RESEARCH, NIH RELEASED A NEW
PUBLIC ACCESS POLICY THAT WILL
ACCELERATE BROAD ACCESS TO
NIH-FUNDED RESEARCH RESULTS.
THE MOST SIGNIFICANT CHANGE FROM
THE PREVIOUS POLICY IS REMOVAL
OF THE 12 MONTH EMBARGO PERIOD
BEFORE MANUSCRIPTS RESULTING
FROM NIH FUNDING MUST BE MADE
PUBLICLY AVAILABLE.
IN ADDITION TO THE UPDATED
POLICY, NIH HAS ALSO ISSUED
SUPPLEMENTAL GUIDANCE ON
PUBLICATION COSTS AND ON
GOVERNMENT USE OF LICENSE AND
RIGHTS.
THE UPDATED POLICY AND
SUPPLEMENTAL GUIDANCE WERE
DEVELOPED AFTER CONSIDERED
FEEDBACK THE NIH RECEIVED ON THE
DRAFT PROPOSALS THROUGH A
REQUEST FOR INFORMATION PROCESS.
REVISED POLICY WILL GO INTO
EFFECT FOR PEER REVIEWED
MANUSCRIPT ACCEPTED ON OR AFTER
DECEMBER 31 OF 2025.
UNTIL THAT TIME, NIH'S CURRENT
PUBLIC ACCESS POLICY FROM 2008
WILL REMAIN IN EFFECT.
BROADLY, THE NEW NIH POLICY AIMS
TO MAXIMIZE AND ACCELERATE
ACCESS TO SCIENTIFIC DATA AND
SCHOLARLY ARTICLES RESULTING
FROM FEDERAL FUNDING AND TO MAKE
RESEARCH RESULTS EASIER TO FIND
AND MORE TRANSPARENT BY USING
METADATA AND PERSISTENT
IDENTIFIERS.
SO, I KNOW A LOT IS GOING ON NOW
OUTSIDE OF THE SCOPE OF MY
REMARKS.
BUT I WANT TO OPEN THE FLOOR TO
HEAR WHAT'S ON YOUR MIND WITH
THE UNDERSTANDING THAT MY
ABILITY TO ANSWER QUESTIONS
ABOUT CHANGES THAT ARE DUE TO
ADMINISTRATION OR NIH PRIORITIES
IS LIKELY TO BE LIMITED AT THIS
TIME.
SO THANK YOU FOR YOUR ATTENTION
AND YOUR UNDERSTANDING.
SO LET ME STOP SHARING.
OKAY.
HOPEFULLY YOU'RE NO LONGER
SEEING MY SCREEN.
AND HAPPY TO TAKE QUESTIONS AT
THIS TIME.
OR I WELCOME COMMENTS FROM MY
COLLEAGUES OR OTHERS ABOUT WHAT
I SHARED.
STEVE?
>> THANKS.
I WANT TO PUBLICLY STATE AGAIN
HOW THE PATIENT COMMUNITY STANDS
WITH NIH AND ALL OF OUR
RESEARCHERS, BOTH INSIDE NIH AS
WELL AS OUTSIDE.
OBVIOUSLY THE WORK THAT WE ALL
DO IS SO IMPORTANT FOR THE
PATIENTS THAT SUFFER FROM
VARIOUS DISEASES NIAMS
REPRESENTS AND TRULY APPRECIATE
YOUR LEADERSHIP WITH ALL THE
AMAZING STAFF AT NIAMS THAT IS
CONTINUING TO PUSH FORWARD THESE
INITIATIVES THAT WILL CHANGE
LIVES.
SO ON BEHALF OF THE ARTHRITIS
COMMUNITY, ARTHRITIS FOUNDATION,
I WANT TO THANK YOU PUBLICLY FOR
THAT.
>> THANK YOU VERY MUCH, STEVE.
WE GREATLY APPRECIATE YOUR
SUPPORT AND THAT OF YOUR
ORGANIZATION AND FOLKS YOU
REPRESENT, ESPECIALLY AT THIS
TIME.
SO THANK YOU.
I DON'T SEE ANY OTHER HANDS UP.
IF I'M MISSING YOUR HAND PLEASE
FEEL FREE TO CHIME IN.
DARREN, ANY OTHER LOGISTICS YOU
WANT TO REMIND FOLKS OF AT THIS
TIME?
>> I WILL JUST REEMPHASIZE THE
NIAMS COUNCIL MAIL, E-MAIL BOX,
NIAMSCOUNCILMAIL@NIH.GOV.
AGAIN, IF THERE ARE FOLLOW-UP
QUESTIONS OR COMMENTS, ABOUT
THIS COUNCIL MEETING, YOU CAN
SEND THEM TO THAT E-MAIL BOX.
AND WE'LL TAKE THEM UNDER
CONSIDERATION.
>> AND DARREN, MAYBE NOW WOULD
BE A GOOD TIME, WHY DON'T WE
SHARE THAT SLIDE THAT WE PUT
TOGETHER EARLIER.
SO, YOU KNOW, THERE'S A LOT OF
CHANGE UNDERWAY, AND WE CAN'T
SPEAK TO SOME OF THE CURRENT
DISCUSSIONS AND, YOU KNOW, ABOUT
POLICIES, ET CETERA.
BUT THERE ARE SOME PUBLICLY
AVAILABLE WEBSITES THAT PROVIDE
UPDATED INFORMATION, FOR
EXAMPLE, ABOUT NIH GRANTS AND
FUNDING INFORMATION, ABOUT
TERMINATED GRANTS, ET CETERA.
DARREN, DO YOU WANT TO SHARE
THAT SLIDE FOR FOLKS?
YEAH.
AND SO THIS IS PUBLICLY
AVAILABLE INFORMATION THAT WILL
BE UPDATED AS THINGS EVOLVE, AND
I WOULD ENCOURAGE YOU TO VISIT
THESE SITES IF YOU HAVE
QUESTIONS ABOUT SOME OF THESE
REALLY IMPORTANT ISSUES.
AND ALSO, JUST TO NOTE AS HAS
BEEN SHARED PUBLICLY, SOME
FUNDING OPPORTUNITIES HAVE BEEN
SUNSETTED, AND OTHERS HAVE BEEN
UPDATED TO ALIGN WITH AGENCY
PRIORITIES.
AND WE ENCOURAGE ALL POTENTIAL
APPLICANTS TO RE-READ FUNDING
OPPORTUNITIES CAREFULLY FOR ANY
POTENTIAL CHANGES PRIOR TO
SUBMISSION TO MAKE SURE THAT
THEIR APPLICATIONS -- YOU KNOW,
REFLECT ANY UPDATED GUIDANCE OR
LANGUAGE, AND ONE NOTE, FOR
EXAMPLE, IS APPLICATIONS NO
LONGER REQUIRE THE PEDP PLANS
FOR ENHANCING DIVERSE
PERSPECTIVES OR SOME OF THE
OTHER DIVERSITY STATEMENTS THAT
WERE REQUIRED IN SOME
APPLICATIONS PREVIOUSLY.
SO THAT HAS CHANGED.
ONCE AGAIN, UPDATES ABOUT NIH
GRANTS AND FUNDING INFORMATION
GENERALLY OR ABOUT ANY
TERMINATED GRANT STATUS IS
AVAILABLE AT THE WEBSITE LISTED
HERE.
WE CAN PUT MORE INFORMATION
ABOUT THOSE SITES IN E COUNCIL
BOOKS IF HELPFUL.
I ALSO JUST WANT TO SAY AS
ALWAYS, AND TO THOSE NEW TO
COUNCIL, I WELCOME YOUR REACHING
OUT AT ANY TIME TO SUGGEST
TOPICS FOR DISCUSSION AT FUTURE
COUNCIL MEETINGS.
SOMETIMES THAT WILL PROMPT US TO
ACT, THOSE THAT ARE SUGGESTING
THE TOPIC, TO PERHAPS OPEN A
DISCUSSION ON THAT TOPIC.
SOMETIMES THOSE TOPICS TURN INTO
FORMAL WORKING GROUPS OF COUNCIL
AS WE'VE HAD FOR CLINICAL TRIALS
AND DATA SCIENCE.
SOMETIMES THEY TURN INTO
DETAILED PRESENTATIONS WITH
MULTIPLE PRESENTERS AS WE HAVE
IN THE LAST COUPLE OF YEARS
RELATED TO PATIENT ENGAGEMENT
AND COMMUNITY ENGAGEMENT.
SO WE REALLY LOOK TO YOU TO HELP
US UNDERSTAND WHAT ARE SOME OF
THE PRESSING BURNING ISSUES THAT
INVESTIGATORS ARE THINKING
ABOUT, OR IMPORTANT
OPPORTUNITIES THAT WE MIGHT BE
ADDRESSING.
IN ADDITION TO OTHER QUESTIONS
YOU MIGHT HAVE ABOUT ALL OF THE
TRANSITIONS HAPPENING NOW.
PLEASE FEEL FREE TO REACH OUT TO
ME OR DARREN SO THAT WE LEVERAGE
YOUR PERSPECTIVES IN FUTURE
COUNCIL MEETINGS.
AND FOR THOSE WHO ARE JOINING US
FOR THE FIRST TIME, THIS IS A
LITTLE BIT ATYPICAL.
USUALLY WE HAVE A LIVELY
DISCUSSION AND IT'S PERFECTLY
FINE THAT WE HAVE AN ABBREVIATED
MEETING TODAY, OUR MAKEUP FOR
JANUARY COUNCIL, SHORTER IN PART
FOR THAT REASON.
WE WEREN'T ABLE TO DO -- TO
PRESENT CONCEPT CLEARANCES, FOR
EXAMPLE, WHICH WOULD NORMALLY
HAVE HAPPENED DURING THE OPEN
SESSION OF COUNCIL.
SO UNLESS THERE ARE ANY OTHER
QUESTIONS, I DON'T WANT TO KEEP
YOU ANY LONGER THAN IS NECESSAR.
PLEASE FEEL FREE TO REACH OUT.
THANK YOU FOR JOINING US.
WELCOME TO OUR NEW MEMBERS AND
OUR AD HOCS.
I THINK THE AD HOCS WILL JOIN US
IN JUNE FOR TYPICAL COUNCIL
MEETING.
FAREWELL TO GAYLE AND THANKS
AGAIN TO MARY AND THANKS TO
DARREN AND SHALANDA FOR
ORGANIZING TODAY'S MEETING.
I THINK I'M ACTUALLY SUPPOSED TO
FORMALLY CLOSE THE MEETING.
SO, LAST CALL FOR ANY QUESTIONS.
AND SEEING NO HANDS, THIS
CONCLUDES THE INSTITUTE'S
116th ADVISORY COUNCIL
MEETING.
WE GREATLY APPRECIATE WHAT WE'VE
HEARD AND INVITE YOUR FEEDBACK
BETWEEN MEETINGS AS WELL, AS I
JUST MENTIONED.
PLEASE FEEL FREE TO REACH OUT TO
DARREN OR ME DIRECTLY FOR ANY
IDEAS FOR FUTURE TOPICS THAT YOU
WANT TO BRING TO THE ATTENTION
OF THE INSTITUTE.
SO, THANK YOU AGAIN FOR JOINING
US.
I THINK ON THAT NOTE WE'LL END
THIS MEETING.
THANK YOU.
[END OF PROGRAM]